Archive for the 'New drugs' Category
Scientists are developing an anti-AIDS pill that can be taken before sex and prevent transmission of the deadly disease.
The successful development of such a treatment would be controversial because it raises ethical questions about the circumstances in which the pill should be taken.
Experts in the disease, which claimed two million lives last year, are involved [...]
January 3rd, 2009 | Posted in Drugs and Medications, HIV/AIDS medicines, New drugs, Research | 1 Comment
Spectrum Pharmaceuticals, Inc. today announced that it has received marketing approval from the U.S. Food and Drug Administration (FDA) for Levoleucovorin for Injection. It is indicated after high-dose methotrexate therapy in patients with osteosarcoma, and to diminish the toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists. LEVOleucovorin [...]
March 9th, 2008 | Posted in Cancer drugs, Drugs and Medications, New drugs | No Comments
A new drug can help alcoholics overcome their addiction by reducing stress-induced cravings, a study has found.
There is already a drug on the market, Revia, which treats alcoholism by reducing the body’s ability to enjoy its effects.
This new drug cuts cravings by taking the edge off of stressful situations which might push recovering alcoholics to [...]
February 16th, 2008 | Posted in Drugs and Medications, New drugs, Research | 1 Comment
Two Baylor College of Medicine researchers in Houston are working on a cocaine vaccine they hope will become the first-ever medication to treat people hooked on the drug. “For people who have a desire to stop using, the vaccine should be very useful,” said Dr. Tom Kosten, a psychiatry professor who is being assisted in [...]
January 4th, 2008 | Posted in Drugs and Medications, New drugs, Research, Vaccines | No Comments
Pharmion Corporation (Nasdaq: PHRM) released interim findings from its Phase 2 trial of Amrubicin in second-line chemo-sensitive small cell lung cancer (SCLC). Amrubicin, the company’s third-generation synthetic anthracycline, is a potent topoisomerase II inhibitor currently in development for the treatment of SCLC. These findings indicate favorable interim results in terms of response rate and survival [...]
November 10th, 2007 | Posted in Cancer drugs, Drugs and Medications, New drugs, Pharmion, Research | No Comments
Merck announced that the extended-release niacin/laropiprant (cordaptive) co administered with simvastatin had significant additive effects on reducing LDL-cholesterol (LDL-C), increasing HDL-cholesterol (HDL-C) and reducing triglyceride levels in a phase III study with patients with primary hypercholesterolemia or mixed dyslipidemia. The results were presented by Merck & Co, Inc. at the American Heart Association 2007 Scientific [...]
November 7th, 2007 | Posted in Cholesterol-modifying medicines, Drugs and Medications, Merck, New drugs, Research | No Comments
A new blood thinner proved better than Plavix, one of the world’s top-selling drugs, at preventing heart problems after procedures to open clogged arteries, doctors reported Sunday. But the new drug also raised the risk of serious bleeding.
People given the experimental drug, prasugrel, were nearly 20 percent less likely to suffer one of the problems [...]
November 4th, 2007 | Posted in Anti-platelet drugs, Blooding-thinning drugs, Eli Lilly, New drugs, Research | No Comments
Bayer HealthCare AG announced today the submission of a Marketing Authorization Application to the European Agency for the Evaluation of Medicinal Products (EMEA) for approval to market rivaroxaban (Xarelto®) for the prevention of venous thromboembolism (VTE) after major orthopedic surgery of the lower limbs. Rivaroxaban is an investigational, oral, once-daily direct Factor Xa inhibitor. Data [...]
November 3rd, 2007 | Posted in Antithrombotic drugs, Bayer, Drugs and Medications, New drugs | No Comments
A phase II trial on axitinib, a new experimental drug for treating patients with cytokine-refractory, metastatic kidney cancer who have a poor response to more traditional drugs has shown promising results according to a new study published in the The Lancet Oncology.
Professor Olivier Rixe of the University of Paris, France, and colleagues assessed the activity [...]
October 30th, 2007 | Posted in Cancer drugs, Drugs and Medications, New drugs, Research | No Comments